Methods of treating parkinson's disease using viral vectors
AssigneesGenzyme Corporation, The Regents of the University of California
InventorsKrystof Bankiewicz, Janet Cunningham
Life of this patent
Estimating the term…
Abstract
Methods of delivering viral vectors, particularly recombinant adeno-associated virus (rAAV) virions, to the central nervous system (CNS) using convection enhanced delivery (CED) are provided. The rAAV virions include a nucleic acid sequence encoding a therapeutic polypeptide. The methods can be used for treating CNS disorders such as for treating Parkinson's Disease.
Claims17
A method for delivering recombinant AAV virions to a subject, comprising administering via convection-enhanced delivery (CED) said rAAV virions into the CNS of the subject, wherein said rAAV virions comprise a nucleic acid sequence encoding a therapeutic polypeptide.
A method for delivering recombinant AAV virions to a subject having a CNS disorder, comprising administering via convection-enhanced delivery (CED) said virions into the CNS of the subject, wherein said virions comprise a nucleic acid sequence encoding a therapeutic polypeptide.
A method for treating a neurodegenerative disease in a subject, said method comprising:
- (a) providing a preparation comprising recombinant adeno-associated virus (rAAV) virions, wherein said virions comprise a nucleic acid sequence that is expressible in transduced cells to provide a therapeutic effect in the subject;
- and
- (b) delivering the preparation to the CNS of the subject using convection-enhanced delivery (CED), wherein said virions transduce neural cells and the nucleic acid sequence is expressed to provide a therapeutic effect in the subject suitable for treating said neurodegenerative disease.
A method of determining levels of dopamine activity in the brain of subject comprising:
- (a) administering a labeled tracer to the subject, wherein binding of the tracer to a cell is indicative of dopamine activity;
- and
- (b) imaging the subject's brain to determine the number of cells which bind the labeled tracer, thereby determining levels of dopamine activity in the subject's brain.
Dependencies are inferred from the claim text.